The use of 18F-fluoromethylcholine PET/CT in differentiating focal nodular hyperplasia from hepatocellular adenoma: A prospective study of diagnostic accuracy

Nuclear Medicine Communications

Volumn 34, Issue 2, 2013, Pages 146-154

  Bieze, Matthanja ^a   Bennink, Roelof J ^a   El Massoudi, Youssef ^a   Phoa, Saffire S K S ^a   Verheij, Joanne ^a   Beuers, Ulrich ^a   Van Gulik, Thomas M ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

18F fluoromethylcholine; focal noular hyperplasia; hepatocellular adenoma; liver; PET CT

Indexed keywords

FLUOROMETHYLCHOLINE F 18; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG; CHOLINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; FLUOROMETHYLCHOLINE;

ADULT; AGED; ARTICLE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER ADENOMA; LIVER FOCAL NODULAR HYPERPLASIA; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PILOT STUDY; PROSPECTIVE STUDY; TUMOR BIOPSY; TUMOR DIFFERENTIATION; TUMOR VOLUME; CLINICAL TRIAL; DIFFERENTIAL DIAGNOSIS; LIVER TUMOR; MIDDLE AGED; NODULAR HYPERPLASIA; PATHOLOGY; SCINTISCANNING; SENSITIVITY AND SPECIFICITY;

ADENOMA, LIVER CELL; ADULT; AGED; CHOLINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; FOCAL NODULAR HYPERPLASIA; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; YOUNG ADULT;

EID: 84871623826     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e32835afe62     Document Type: Article

References (29)

1. Becker YT, Raiford DS, Webb L, Wright JK, Chapman WC, Pinson CW. Rupture and hemorrhage of hepatic focal nodular hyperplasia. Am Surg 1995; 61:210-214.
2. Cherqui D, Rahmouni A, Charlotte F, Boulahdour H, Metreau JM, Meignan M, et al. Management of focal nodular hyperplasia and hepatocellular adenoma in young women: a series of 41 patients with clinical, radiological, and pathological correlations. Hepatology 1995; 22:1674-1681.
3. Reddy KR, Kligerman S, Levi J, Livingstone A, Molina E, Franceschi D, et al. Benign and solid tumors of the liver: relationship to sex, age, size of tumors, and outcome. Am Surg 2001; 67:173-178.
4. Dokmak S, Paradis V, Vilgrain V, Sauvanet A, Farges O, Valla D, et al. A single-center surgical experience of 122 patients with single and multiple hepatocellular adenomas. Gastroenterology 2009; 137:1698-1705.
5. Stoot JH, Coelen RJ, De Jong MC, Dejong CH. Malignant transformation of hepatocellular adenomas into hepatocellular carcinomas: a systematic review including more than 1600 adenoma cases. HPB (Oxford) 2010; 12:509-522.
6. Nagorney DM. Benign hepatic tumors: focal nodular hyperplasia and hepatocellular adenoma. World J Surg 1995; 19:13-18.
7. Weimann A, Ringe B, Klempnauer J, Lamesch P, Gratz KF, Prokop M, et al. Benign liver tumors: differential diagnosis and indications for surgery. World J Surg 1997; 21:983-990.
8. Belghiti J, Pateron D, Panis Y, Vilgrain V, Flejou JF, Benhamou JP, et al. Resection of presumed benign liver tumours. Br J Surg 1993; 80:380-383.
9. Terkivatan T, deWilt JH, de Man RA, van Rijn RR, Zondervan PE, Tilanus HW, et al. Indications and long-term outcome of treatment for benign hepatic tumors: a critical appraisal. Arch Surg 2001; 136:1033-1038.
10. Foster JH, Berman MM. The malignant transformation of liver cell adenomas. Arch Surg 1994; 129:712-717.
11. Van den Esschert JW. Imaging modalities for focal nodular hyperplasia and hepatocellular adenoma. Digest Surg 2010; 27:46-55.
12. Michel V, Bakovic M. The solute carrier 44A1 is a mitochondrial protein and mediates choline transport. FASEB J 2009; 23:2749-2758.
13. Zeisel SH. Importance of methyl donors during reproduction. Am J Clin Nutr 2009; 89:673S-677S.
14. DeGrado TR, Reiman RE, Price DT, Wang S, Coleman RE. Pharmacokinetics and radiation dosimetry of 18F-fluorocholine. J Nucl Med 2002; 43:92-96.
15. Bumsel F, Huchet V, Arrive L. Positron emission tomography (PET/CT) using fluoro-choline allows to differentiate between adenoma and focal nodular hyperplasia. Hepatology 2007; 19 (Suppl 1):433A.
16. Van den Esschert JW, Bieze M, Beuers UH, van Gulik TM, Bennink RJ. Differentiation of hepatocellular adenoma and focal nodular hyperplasia using (18)F-fluorocholine PET/CT. Eur J Nucl Med Mol Imaging 2010; 38:436-440.
17. DeGrado TR, Baldwin SW, Wang S, Orr MD, Liao RP, Friedman HS, et al. Synthesis and evaluation of (18)F-labeled choline analogs as oncologic PET tracers. J Nucl Med 2001; 42:1805-1814.
18. Bioulac-Sage P, Blanc JF, Rebouissou S, Balabaud C, Zucman-Rossi J. Genotype phenotype classification of hepatocellular adenoma. World J Gastroenterol 2007; 13:2649-2654.
19. Bioulac-Sage P, Laumonier H, Rullier A, Cubel G, Laurent C, Zucman-Rossi J, et al. Over-expression of glutamine synthetase in focal nodular hyperplasia: a novel easy diagnostic tool in surgical pathology. Liver Int 2009; 29:459-465.
20. Newcombe RG. Two-sided confidence intervals for the single proportion: comparison of seven methods. Stat Med 1998; 17:857-872.
21. Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1994; 271:389-391.
22. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B.What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994; 271:703-707.
23. Talbot JN, Fartoux L, Balogova S, Nataf V, Kerrou K, Gutman F, et al. Detection of hepatocellular carcinoma with PET/CT: a prospective comparison of 18F-fluorocholine and 18F-FDG in patients with cirrhosis or chronic liver disease. J Nucl Med 2010; 51:1699-1706.
24. Bioulac-Sage P, Laumonier H, Couchy G, Le BB, Sa CA, Rullier A, et al. Hepatocellular adenoma management and phenotypic classification: the Bordeaux experience. Hepatology 2009; 50:481-489.
25. Talbot JN, Gutman F, Fartoux L, Grange JD, Ganne N, Kerrou K, et al. PET/CT in patients with hepatocellular carcinoma using [(18)F]fluorocholine: preliminary comparison with [(18)F]FDG PET/CT. Eur J Nucl Med Mol Imaging 2006; 33:1285-1289.
26. van Aalten SM,Verheij J,Terkivatan T, Dwarkasing RS, deMan RA, Ijzermans JN. Validation of a liver adenoma classification system in a tertiary referral centre: implications for clinical practice. J Hepatol 2010; 55:120-125.
27. Sasaki T. [11C]choline uptake in regenerating liver after partial hepatectomy or CCl4-administration. Nucl Med Biol 2004; 31:269-275.
28. Kwee SA, DeGrado TR, Talbot JN, Gutman F, Coel MN. Cancer imaging with fluorine-18-labeled choline derivatives. Semin Nucl Med 2007; 37:420-428.
29. International Working Party. Terminology of nodular hepatocellular lesions. Hepatology 1995; 22:983-993.